# The Efficacy and Safety of Dalpiciclib Plus Endocrine Therapy in HR-positive / HER2-negative Advanced Breast Cancer Patients With Visceral Crisis

> **NCT05431504** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Cancer Institute and Hospital, Chinese Academy of Medical Sciences** · enrollment: 53 (estimated)

## Conditions studied

- Advanced Breast Cancer

## Interventions

- **DRUG:** Dalpiciclib in combination with endocrine therapy by Physicians choice

## Key facts

- **NCT ID:** NCT05431504
- **Lead sponsor:** Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2022-06
- **Primary completion:** 2025-12
- **Final completion:** 2027-12
- **Target enrollment:** 53 (ESTIMATED)
- **Last updated:** 2022-06-24

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05431504

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05431504, "The Efficacy and Safety of Dalpiciclib Plus Endocrine Therapy in HR-positive / HER2-negative Advanced Breast Cancer Patients With Visceral Crisis". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05431504. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*